Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 5/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19948765 | 1.00 | ESR2 (0.55) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL24913965 | 0.90 | ESR2 (0.55) | ESR2NR1H2MAPK1ABHD6ADORA1 | |
| SCHEMBL30156742 | 0.90 | ESR2 (0.55) | ESR2NR1H2MAPK1ABHD6ADORA1 | |
| SCHEMBL30260187 | 0.86 | ESR2 (0.60) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL17583921 | 0.86 | ESR2 (0.60) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL31447559 | 0.85 | NR1H2 (0.60) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL21469392 | 0.85 | ESR2 (0.55) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL17018770 | 0.85 | NR1H2 (0.60) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL19642882 | 0.85 | ESR2 (0.55) | ESR2NR1H2MAPK1ABHD6UCHL1 | |
| SCHEMBL29405503 | 0.85 | ESR2 (0.55) | ESR2NR1H2MAPK1ABHD6UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516059-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2026-01-06 | — | — | US | disclosed |
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2024-11-21 | — | — | US | disclosed |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383889-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | ESR2 3009/4885NR1H2 1225/4885MAPK1 639/4885 |
| US-11242343-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ESR2 3009/4885NR1H2 1225/4885MAPK1 639/4885 |
| US-20220227752-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | ESR2 3009/4885NR1H2 1225/4885MAPK1 639/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | ESR2 2188/4885NR1H2 309/4885MAPK1 795/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | ESR2 2859/4885NR1H2 1187/4885MAPK1 956/4885 |
| US-11891388-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | ESR2 3009/4885NR1H2 1225/4885MAPK1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.